Aptamer Group Plc AI Stock Analysis
Want to see GB:APTA full AI Analyst Report?
Aptamer Group Plc (APTA) AI Stock Analysis
Aptamer Group Plc
(LSE:APTA)
Aptamer Group scores low primarily because of its financial profile: persistent operating losses, a cost base around twice revenue, and £2.30m of free cash outflow keep the business reliant on equity funding, with dilution risk if revenue does not scale. Offsetting positives are a rebuilt, essentially debt-free balance sheet (£5.74m equity, £0.17m debt), two consecutive years of revenue growth to £1.54m, and improving gross margin. Technically, a recent bounce above the 20- and 50-day averages is encouraging but the stock remains far below its 200-day average and is now overbought, while negative earnings and no dividend leave valuation unsupportive.
Aptamer Group Plc (APTA) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 9.88M
- Dividend Yield
- ―
- Average Volume (3M)
- 6.06M
- Price to Earnings (P/E)
- -9.5
- Beta (1Y)
- 0.96
- Revenue Growth
- 28.35%
- EPS Growth
- 50.00%
- Country
- UK
- Employees
- 34
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Aptamer Group Plc Business Overview & Revenue Model
Company Description
Aptamer Group plc, an international company headquartered in York, United Kingdom, specializes in providing advanced binders for applications spanning research, diagnostics, and therapeutics. Their innovative binder technology is engineered to resolv...
Aptamer Group Plc Financial Statement Overview
Summary
Financials remain weak overall. Revenue grew for a second straight year to £1.54m and gross margin improved to 37.1%, but the cost base is still roughly double sales, producing a £2.85m operating loss and a deeply negative return on equity. Free cash outflow widened to £2.30m and the company has never generated positive operating cash, leaving it dependent on external funding. The one clear strength is the recapitalised balance sheet: equity rebuilt to £5.74m with debt cut to a negligible £0.17m, giving an essentially debt-free structure that buys time but not self-sufficiency.
Income Statement
22NegativeBalance Sheet
58NeutralCash Flow
20Very Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.54M | 1.54M | 1.20M | 860.00K | 4.04M | 1.75M |
| Gross Profit | 573.00K | 573.00K | 350.00K | 250.00K | 2.69M | 359.00K |
| EBITDA | -2.60M | -2.60M | -2.28M | -2.81M | -2.20M | -7.36M |
| Net Income | -1.86M | -1.86M | -2.42M | -2.96M | -2.09M | -7.84M |
Balance Sheet | ||||||
| Total Assets | 7.18M | 7.18M | 2.83M | 2.77M | 11.52M | 2.75M |
| Cash, Cash Equivalents and Short-Term Investments | 4.36M | 4.36M | 1.06M | 870.00K | 6.69M | 234.00K |
| Total Debt | 170.00K | 170.00K | 491.00K | 817.00K | 1.31M | 1.08M |
| Total Liabilities | 1.44M | 1.44M | 1.45M | 1.88M | 3.47M | 2.45M |
| Stockholders Equity | 5.74M | 5.74M | 1.38M | 887.00K | 8.05M | 304.00K |
Cash Flow | ||||||
| Free Cash Flow | -2.30M | -2.30M | -2.01M | -2.41M | -2.79M | -6.09M |
| Operating Cash Flow | -2.13M | -2.13M | -2.00M | -2.28M | -2.38M | -4.06M |
| Investing Cash Flow | -253.00K | -253.00K | -92.00K | -122.00K | -418.00K | -2.03M |
| Financing Cash Flow | 5.68M | 5.68M | 2.28M | 3.04M | 9.12M | -365.00K |
Aptamer Group Plc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:APTA, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.32, and below the 200-day MA of 0.52, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 39.97 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:APTA.
Aptamer Group Plc Peers Comparison
Overall Rating
GB:BVXP89Outperform
GB:APTA40Underperform
GB:AVCT40Underperform
GB:FAB40Underperform
GB:OBD40Underperform
GB:AREC33Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 89Outperform | GBP 101.88M | 13.45 | 67.81% | 7.69% | -1.10% | 0.32% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 40Underperform | GBP 9.88M | -9.50 | -46.61% | ― | 28.35% | 50.00% | |
| 40Underperform | GBP 287.20M | -6.47 | -1293.07% | ― | ― | ― | |
| 40Underperform | GBP 5.32M | -4.29 | -97.87% | ― | 7.38% | 44.13% | |
| 40Underperform | GBP 14.11M | -0.26 | -451.74% | ― | 33.37% | 86.41% | |
| 33Underperform | GBP 32.39M | 143.00 | 3.75% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:APTA | Aptamer Group Plc | 0.28 | -0.65 | -69.35% | |
| GB:AVCT | Avacta Group plc | 59.00 | -13.50 | -18.62% | |
| GB:BVXP | Bioventix plc | 1950.00 | 45.25 | 2.38% | |
| GB:OBD | Oxford BioDynamics | 0.10 | -0.18 | -62.50% | |
| GB:FAB | Fusion Antibodies Plc | 4.25 | -7.50 | -63.83% | |
| GB:AREC | Arecor Therapeutics PLC | 71.50 | -2.50 | -3.38% |
Aptamer Group Plc Corporate Events
Aptamer Group lifts revenue and cash as licensing and pharma demand deepen
PositiveAptamer Group reported full-year revenue of £1.5 million, up 28% year-on-year, supported by growing demand for its Optimer technology and repeat work with multiple top 20 pharmaceutical companies. A £4.1 million equity raise lifted the year-end cash...
Aptamer Group Sets Analyst and Investor Meetings for Full-Year Results
PositiveAptamer Group plc plans to release its full-year results for the period ended 30 June 2026 on 13 October, alongside a scheduled online briefing for analysts hosted by Chief Executive Dr Arron Tolley and Chief Financial Officer Andrew Rapson. The comp...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026